The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy
Open accessAbstract
The variety of factors and events involved in neurodegeneration renders the subject a major challenge. Neurodegenerative disorders include a number of different pathological conditions, which share similar critical metabolic processes, such as protein aggregation and oxidative stress, both of which are associated with the involvement of metal ions. In this review, Alzheimer's disease, Parkinson's disease and prion disease are discussed, with the aim of identifying common trends underlying these devastating neurological conditions. Chelation therapy could be a valuable therapeutic approach, since metals are considered to be a pharmacological target for the rationale design of new therapeutic agents directed towards the treatment of neurodegeneration. British Journal of Pharmacology (2005) 146, 1041–1059. doi:10.1038/sj.bjp.0706416
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In Parkinson's disease, when brain iron concentration is increased, neuromelanin may become saturated and iron would be bound to low affinity sites, so that some bound iron is redox-active and potentially toxic.
“However, in PD, when brain iron concentration is increased, the pigment may become saturated and iron would be bound to low affinity sites, so that some amount of the bound iron is redox-active and potentially toxic (Gaeta and Hider, 2005).”
From Iron, Oxidative Stress and Health (2012) · cites this paper as Gaeta and Hider, 2005
When amyloid-beta deposits accumulate sufficiently for oxidative stress to occur, it induces its own production, starting a vicious cycle.
“Gaeta and Hider (2005) reported that when the Aβ deposits accumulate sufficiently for oxidative stress to occur; it induces its own production, starting a vicious cycle.”
From Iron, Oxidative Stress and Health (2012) · cites this paper as Gaeta and Hider (2005)
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864 · see citing works
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359 · see citing works
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291 · see citing works
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506 · see citing works
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990 · see citing works
Copper, iron and zinc in Alzheimer's disease senile plaques
Lovell, M. A., Robertson, J. D., Teesdale, W. J., Campbell, J. L., & Markesbery, W. R. (1998) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(98)00092-6 · Cited by 2,120 · see citing works
Compston, A., & Coles, A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08220-x · Cited by 1,743 · see citing works
Cherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y.-S., et al. (2001) · Neuron · doi:10.1016/s0896-6273(01)00317-8 · Cited by 1,447 · see citing works
Dexter, D. T., Wells, F. R., Lee, A. J., Agid, F., Agid, Y., Jenner, P., & Marsden, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb07264.x · Cited by 1,149 · see citing works
Amyloid β-Protein Fibrillogenesis
Walsh, D. M., Hartley, D. M., Kusumoto, Y., Fezoui, Y., Condron, M. M., Lomakin, A., Benedek, G. B., Selkoe, D. J., & Teplow, D. B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.36.25945 · Cited by 1,046 · see citing works
Brunk, U. T., & Terman, A. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00959-0 · Cited by 919 · see citing works
Dementia and Alzheimer Disease Incidence: A Prospective Cohort Study
Kukull, W. A., Higdon, R., Bowen, J. D., McCormick, W. C., Teri, L., Schellenberg, G. D., van Belle, G., Jolley, L., & Larson, E. B. (2002) · Archives of Neurology · doi:10.1001/archneur.59.11.1737 · Cited by 806 · see citing works
Zecca, L., Gallorini, M., Schünemann, V., Trautwein, A. X., Gerlach, M., Riederer, P., Vezzoni, P., & Tampellini, D. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00186.x · Cited by 401 · see citing works
Raymond, K. N., Müller, G., & Matzanke, B. F. (1984) · Topics in Current Chemistry · doi:10.1007/3-540-13099-3_2 · Cited by 357 · cited 1× · see citing works
“…10 6M, [Ligand]total¼ 10 5M at pH 7.4) value is a more useful parameter than the conventional stability constant to assess the ligand affinity for the metal (Raymond et al., 1984; Liu & Hider, 2002a); for clinically useful iron scavengers, a pFe3þ value X20 (Table 1) is considered to be essential.”
BackgroundInfluentialConnor, J. R., Snyder, B. S., Arosio, P., Loeffler, D. A., & LeWitt, P. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.65020717.x · Cited by 317 · cited 1× · see citing works
“Interestingly, a study, in which antibodies against ferritin were used, indicated no increase in neuronal ferritin, suggesting that the elevated iron is unbound and therefore potentially reactive (Connor et al., 1995).”
BackgroundMetal complexing agents as therapies for Alzheimer’s disease
Bush, A. I. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00120-3 · Cited by 310 · see citing works
Design of iron chelators with therapeutic application
Liu, Z. D., & Hider, R. C. (2002) · Coordination Chemistry Reviews · doi:10.1016/s0010-8545(02)00050-4 · Cited by 287 · see citing works
Self-citationAbeysinghe, R. D., Roberts, P. J., Cooper, C. E., MacLean, K. H., Hider, R. C., & Porter, J. B. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.14.7965 · Cited by 70 · see citing works
Self-citationEmerging β-Amyloid Therapies for the Treatment of Alzheimers Disease
Conway, K., Baxter, E., Felsenstein, K., & Reitz, A. (2003) · Current Pharmaceutical Design · doi:10.2174/1381612033391649 · Cited by 40 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Multi-target-Directed Ligands To Combat Neurodegenerative Diseases
Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152 · see citing works
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554 · see citing works
Copper and iron disorders of the brain
Madsen, E., & Gitlin, J. D. (2007) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.30.051606.094232 · Cited by 557 · see citing works
Scott, L. E., & Orvig, C. (2009) · Chemical Reviews · doi:10.1021/cr9000176 · Cited by 332 · see citing works
Metal based neurodegenerative diseases—From molecular mechanisms to therapeutic strategies
Crichton, R. R., Dexter, D. T., & Ward, R. J. (2008) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2007.10.019 · Cited by 252 · see citing works
Metal ions, Alzheimer's disease and chelation therapy
Budimir, A. (2011) · Acta Pharmaceutica · doi:10.2478/v10007-011-0006-6 · Cited by 202 · see citing works
Minding metals: Tailoring multifunctional chelating agents for neurodegenerative disease
Perez, L. R., & Franz, K. J. (2010) · Dalton Trans. · doi:10.1039/b919237a · Cited by 156 · see citing works
Design of iron chelators with therapeutic application
Zhou, T., Ma, Y., Kong, X., & Hider, R. C. (2012) · Dalton Transactions · doi:10.1039/c2dt12159j · Cited by 136 · see citing works
Self-citationIron: A New Target for Pharmacological Intervention in Neurodegenerative Diseases
Whitnall, M., & Richardson, D. R. (2006) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2006.08.008 · Cited by 113 · see citing works
Hassan, W., Barroso Silva, C., Mohammadzai, I. U., Teixeira da Rocha, J., & Landeira-Fernandez, J. (2014) · Current Neuropharmacology · doi:10.2174/1570159x11666131120232135 · Cited by 100 · see citing works
Xu, P., Zhang, M., Sheng, R., & Ma, Y. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.12.045 · Cited by 92 · see citing works
Dopamine promotes cellular iron accumulation and oxidative stress responses in macrophages
Dichtl, S., Haschka, D., Nairz, M., Seifert, M., Volani, C., Lutz, O., & Weiss, G. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.12.001 · Cited by 76 · see citing works
Iron, oxidative stress and the example of solar ultraviolet a radiation.
Aroun, A., Zhong, J. L., Tyrrell, R. M., & Pourzand, C. (2012) · Photochemical & Photobiological Sciences · doi:10.1039/c1pp05204g · Cited by 74 · see citing works
Recent developments on 3-hydroxy-4-pyridinones with respect to their clinical applications
Santos, M. A. (2008) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2008.01.033 · Cited by 54 · see citing works
D'Acunto, C. W., Kaplánek, R., Gbelcová, H., Kejík, Z., Bříza, T., Vasina, L., Havlík, M., Ruml, T., & Král, V. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.02.084 · Cited by 26 · see citing works
Iron, Oxidative Stress and Health
Udipi, S., Ghugre, P., & Gokhale, C. (2012) · Oxidative Stress - Molecular Mechanisms and Biological Effects · doi:10.5772/34975 · Cited by 17 · see citing works
Part, K., Künnis-Beres, K., Poska, H., Land, T., Shimmo, R., & Zetterström Fernaeus, S. (2015) · Brain Research · doi:10.1016/j.brainres.2015.09.034 · Cited by 16 · see citing works
Hague, T., Andrews, P. L. R., Barker, J., & Naughton, D. P. (2006) · Behavioural Pharmacology · doi:10.1097/00008877-200609000-00008 · Cited by 12 · see citing works
- Authors
- Gaeta, A., & Hider, R. C.
- Affiliations
- King's College London (GB)
- Corresponding author
- Gaeta, Alessandra
- ORCID
- Hider, Robert C
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2005-12
- Volume
- 146
- Issue
- 8
- Pages
- 1041-1059
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- PMC
- PMC1751240
- OpenAlex
- W1538748480
- Cited by
- 411
- References
- 19
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 19 · 2023: 14 · 2022: 17 · 2021: 12 · 2020: 22 · 2019: 18 · 2018: 14 · 2017: 22 · 2016: 18 · 2015: 19 · 2014: 23 · 2013: 18 · 2012: 26
- FWCI
- 2.71
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- British Journal of Pharmacology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Physical Sciences › Environmental Science › Health, Toxicology and Mutagenesis › Heavy Metal Exposure and Toxicity
- Health Sciences › Nursing › Nutrition and Dietetics › Trace Elements in Health
- Keywords
- metal ions, neurodegeneration, chelation therapy, Alzheimer's disease, Parkinson's disease, prion disease, protein aggregation, oxidative stress, metal-based drugs
- MeSH terms
- Alzheimer Disease, Animals, Chelating Agents, Copper, Humans, Ions, Iron, Manganese, Metals, Parkinson Disease, Prions, Proteins, Amyloid beta-Peptides, Prion Diseases, Oxidative Stress, Neurodegenerative Diseases, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
